6 Results

People

  1. Drilon
    Drilon
  2. Kris
    Kris
  3. Ni
    Ni
  4. Riely
    Riely
  5. Bergagnini
    Bergagnini
  6. Bushnell
    Bushnell
  7. Canestraro
    Canestraro
  8. Delasos
    Delasos
  9. Francis
    Francis
  10. Ginsberg
    Ginsberg

Groups

  1. Department of Medicine (6)
  2. Solid Tumor Oncology Division (6)
  3. Thoracic Oncology (6)
  4. Biostatistics Service (2)
  5. Department of Pathology and Laboratory Medicine (2)
  6. Epidemiology and Biostatistics (2)
  7. Nursing (2)
  8. Radiology, Department of (2)
  9. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  10. Body Imaging Service (1)
  1. "ret fusion"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (2)
Groups
  1. Department of Medicine (6)
  2. Solid Tumor Oncology Division (6)
  3. Thoracic Oncology (6)
  4. Biostatistics Service (2)
  5. Department of Pathology and Laboratory Medicine (2)
  6. Epidemiology and Biostatistics (2)

More Groups

People
  1. Alexander Drilon (6)
  2. Ai Ni (2)
  3. Gregory Riely (2)
  4. Mark Kris (2)
  5. Andrea Moy (1)
  6. Andrew Plodkowski (1)

More People

Years
  1. 2025 (1)
  2. 2023 (1)
  3. 2020 (1)
  4. 2019 (1)
  5. 2018 (1)
  6. 2017 (1)
Publications
  1. Journal of Thoracic Oncology (4)
  2. Frontiers in Oncology (1)
  3. JTO Clinical and Research Reports (1)
Publishers
  1. Elsevier Inc. (4)
  2. Elsevier B.V. (1)
  3. Frontiers Media S.A. (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mucocutaneous adverse events in patients with cancer treated with the highly selective RET kinase inhibitor selpercatinib (LOXO-292)
    Journal Article

    Reingold, R. E.; Parisi, R.; Harada, G.; Moy, A. P.; Dranitsaris, G.; Francis, J. H.; Canestraro, J.; Lester, J. A.; Kaplanis, L. A.; Liu, D.; more...
    JTO Clinical and Research Reports (2025)

    Fulltext@MSK | Save
  • Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer
    Journal Article

    Goldman, J. W.; Sholl, L. M.; Dacic, S.; Fishbein, M. C.; Murciano-Goroff, Y. R.; Rajaram, R.; Szymczak, S.; Szpurka, A. M.; Chao, B. H.; Drilon, A.
    Frontiers in Oncology (2023)

    Fulltext@MSK | Save
  • RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies
    Journal Article

    Solomon, B. J.; Tan, L.; Lin, J. J.; Wong, S. Q.; Hollizeck, S.; Ebata, K.; Tuch, B. B.; Yoda, S.; Gainor, J. F.; Sequist, L. V.; more...
    Journal of Thoracic Oncology (2020)

    Fulltext@MSK | Save
  • Registrational results of LIBRETTO-001: A phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers
    Meeting Abstract

    Drilon, A.; Oxnard, G.; Wirth, L.; Besse, B.; Gautschi, O.; Tan, S. W. D.; Loong, H.; Bauer, T.; Kim, Y. J.; Horiike, A.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET–rearranged lung cancers
    Journal Article

    Drilon, A.; Lin, J. J.; Filleron, T.; Ni, A.; Milia, J.; Bergagnini, I.; Hatzoglou, V.; Velcheti, V.; Offin, M.; Li, B.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • A phase 2 study of cabozantinib for patients with advanced RET-rearranged lung cancers
    Meeting Abstract

    Drilon, A.; Somwar, R.; Smith, R.; Delasos, L.; Albano, M.; Van Voorthuyson, M.; Wang, L.; Rekhtman, N.; Ni, A.; Plodkowski, A.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save